Search Results for keywords:"false designation of origin"

Found 2 results

Search Results: keywords:"false designation of origin"

💰 Only
Oldest Newest
  • 2021-01439 — Certain Plant-Derived Recombinant Human Serum Albumins (“rHSA”) and Products Containing Same; Notice of Institution of Investigation
    Type:Notice
    Citation:86 FR 6916
    Reading Time:about 5 minutes

    A complaint was filed by Ventria Bioscience Inc. with the U.S. International Trade Commission alleging violations of section 337 of the Tariff Act of 1930. The complaint concerns the importation and sale of plant-derived recombinant human serum albumins (rHSA) and related products, which allegedly infringe upon certain U.S. patents and are falsely designated in origin. The U.S. International Trade Commission has initiated an investigation and will determine whether to issue exclusion and cease and desist orders against the respondents named in the complaint.

    Simple Explanation

    A company thinks some other people are bringing in special plant-made proteins without permission and pretending they made them. Now, a big rule-checking group is looking into it to see if they should stop those people from doing it.

  • 2025-01785 — Certain Products Containing Tirzepatide and Products Purporting To Contain Tirzepatide; Notice of a Commission Determination Not To Review an Initial Determination Finding Respondents in Violation of Section 337; Request for Written Submissions on Remedy, the Public Interest, and Bonding
    Type:Notice
    Citation:90 FR 8299
    Reading Time:about 9 minutes

    The U.S. International Trade Commission (ITC) has decided not to review a decision by an administrative law judge regarding violations of section 337, involving products containing tirzepatide. These violations included trademark infringement, false designation of origin, and false advertising by certain companies. The ITC is now asking for written submissions from different parties on potential remedies, public interests, and bonding issues. If a remedy is ordered, it might include stopping these products from entering the U.S. or cease and desist orders against the companies involved.

    Simple Explanation

    The U.S. International Trade Commission (ITC) found some companies breaking rules with their tirzepatide products by doing things like fake advertising, and now they are asking people for ideas on how to fix it, like stopping these products from coming to the U.S.